SGN-516 is under clinical development by SGN Nanopharma and currently in Phase I for Diabetic Neuropathy. According to GlobalData, Phase I drugs for Diabetic Neuropathy have an 88% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how SGN-516’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
SGN Nanopharma overview
SGN Nanopharma is a clinical-stage nanomedicine company. It combines its proprietary nanotechnologies with structural biology to develop nanotherapeutics. The company focuses on developing novel therapies, reformulating FDA approved, sub-optimal drugs, and active pharmaceutical ingredients (APIs). It utilizes Micellar Nanoparticle (MNP) technology platform which leads to finer particle sizes and stable nanoemulsions. SGN Nanopharma nanotechnology enables reformulation and delivery of poorly-water-soluble compounds such as cannabinoids. The company introduced a MNP-Cyclosporine formulation for dry eye disease in India and operates through its subsidiary in India. It holds rights to two pending patent families with the United States Patent and Trademark Office (USPTO). SGN Nanopharma is headquartered in Tampa, Florida, the US.
For a complete picture of SGN-516’s drug-specific PTSR and LoA scores, buy the report here.